People: Agios Pharmaceuticals Inc (AGIO.O)

AGIO.O on Nasdaq

119.62USD
19 Dec 2014
Price Change (% chg)

$-0.10 (-0.08%)
Prev Close
$119.72
Open
$120.90
Day's High
$120.90
Day's Low
$117.04
Volume
1,932,916
Avg. Vol
959,573
52-wk High
$124.39
52-wk Low
$21.33

Search Stocks

Summary

Name Age Since Current Position

David Schenkein

56 2013 Chief Executive Officer, Director

Duncan Higgons

59 Chief Operating Officer

Shin-San Michael Su

2012 Senior Vice President - research & development

Scott Biller

58 Chief Scientific Officer

Chris Bowden

2014 Chief Medical Officer

Lewis Cantley

65 Independent Director

Paul Clancy

52 2013 Independent Director

Douglas Cole

48 2013 Independent Director

Kaye Foster-Cheek

53 2014 Independent Director

Perry Karsen

58 2013 Independent Director

John Maraganore

51 2011 Independent Director

Robert Nelsen

51 Independent Director

Kevin Starr

51 2013 Independent Director

Marc Tessier-Lavigne

54 2011 Independent Director

Glenn Goddard

43 2013 Vice President - Finance

Biographies

Name Description

David Schenkein

Dr. David P. Schenkein, M.D is a Chief Executive Officer, Director of Agios Pharmaceuticals Inc. Prior to that, he was the Senior Vice President, Clinical Hematology Oncology at Genentech, Inc. in San Francisco. He has been a Medical Oncologist and Hematologist for over 20 years and while in San Francisco was an Adjunct Clinical Professor of Medicine Oncology at Stanford University School of Medicine.

Duncan Higgons

Mr. Duncan Higgons is the Chief Operating Officer for Agios Pharmaceuticals, Inc. He worked at Archemix Corporation, where he served as President, Chief Operating Officer and Interim Chief Executive Officer. He worked as the Chief Commercial Officer at TransForm Pharmaceuticals. He has also held positions at Alkermes, Inc. as Senior Vice President of Business Development and Marketing; Eli Lilly & Co., where he served in a variety of senior sales and marketing functions; and Baxter International.

Shin-San Michael Su

Dr. Shin-San Michael Su is the Senior Vice President - research & development of Agios Pharmaceuticals, Inc. Dr. Su brings more than 20 years of organization, project management and scientific experience in the biotechnology industry to Agios. Most recently, from 2004 to 2006 he served as general director and vice president of the Biomedical Engineering Research Laboratory (BEL) at ITRI in Taiwan. Prior to that, he spent 14 years in a number of roles, concluding his tenure as program executive and vice president of the Novartis kinase collaboration for Vertex Pharmaceuticals, a publicly-traded a pharmaceutical company.

Scott Biller

Dr. Scott Biller is the Chief Scientific Officer of Agios Pharmaceuticals, Inc. Prior to that, he was Vice President and Head of global discovery chemistry at the Novartis Institutes for Biomedical Research (NIBR). Before that, he held the positions of Vice President, pharmaceutical candidate optimization at the Bristol Myers Squibb (BMS) Pharmaceutical Research Institute and Executive Director of drug discovery chemistry for the BMS research site in Lawrenceville.

Chris Bowden

Dr. Chris Bowden, M.D. is Chief Medical Officer of the Company. During Dr. Bowden’s eight years at Genentech, he was responsible for the successful development of a number of novel oncology medicines. He led the teams responsible for the development and global registrations of several marketed cancer medicines, including Zelboraf® indicated for the treatment of BRAF V600E mutant-positive metastatic melanoma, Tarceva® indicated for the first line therapy of patients with non-small cell lung cancer whose tumors have an activating mutation of the Epidermal Growth Factor receptor (EGFR), and Erivedge® for patients with unresectable, locally advanced or metastatic basal cell carcinoma. From 2003 to 2006, Dr. Bowden was the executive director for EMEA (Europe, Middle East, Africa) regions for Bristol-Myers Squibb. In this role, he led medical affairs strategies for cancer, immunology and pain medicines. Earlier, Dr. Bowden held positions of increasing responsibility in oncology clinical development, Phases I-III, at Pharmacia Corporation and Janssen Pharmaceutica. Prior to his industry experience, Dr. Bowden was on the oncology faculty at the University of Virginia Health Science Center where he participated in numerous industry and cooperative group trials. Dr. Bowden received his medical degree from Hahnemann University School of Medicine in Philadelphia followed by internal medicine training at Roger Williams Medical Center and the Providence VA Medical Center, Rhode Island. He completed his medical oncology fellowship at the National Cancer Institute Medicine Branch. Dr. Bowden is board certified in internal medicine and medical oncology.

Lewis Cantley

Dr. Lewis C. Cantley, Ph.D. is an Independent Director of Agios Pharmaceuticals, Inc. Dr. Cantley has served as a director of the Cancer Center at Weill Cornell Medical College and New York-Presbyterian Hospital since October 2012. Prior to that, from 1992 to 2012 Dr. Cantley was a professor of systems biology at Harvard Medical School and chief of the division of Signal Transduction at Beth Israel Deaconess Medical Center, a major teaching hospital of Harvard Medical School in Boston. From 2007 to 2012, Dr. Cantley also served as director of the Cancer Center at Beth Israel Deaconess Medical Center. Dr. Cantley is a member of the American Academy of Arts and Sciences and the National Academy of Sciences, and serves on the editorial boards of the journals Cell and the Journal of Cell Biology.

Paul Clancy

Mr. Paul J. Clancy is an Independent Director of Agios Pharmaceuticals, Inc. Mr. Clancy has been Executive Vice President, Finance and Chief Financial Officer of Biogen Idec Inc., a publicly-traded biopharmaceutical company, since August 2007. Mr. Clancy joined Biogen in 2001 and has held several senior executive positions with Biogen, including Vice President of Business Planning, Portfolio Management and U.S. Marketing, and Senior Vice President of Finance with responsibilities for the Treasury, Tax, Investor Relations and Business Planning groups. Prior to that, he spent 13 years at PepsiCo, a food and beverage company, serving in a range of financial and general management positions. Mr. Clancy received his B.S. in Finance from Babson College and M.B.A. from Columbia University. The Company believes Mr. Clancy's qualifications to serve on the Board include his 25 years of experience in finance and management positions at publicly-traded companies, including six years as the chief financial officer of a publicly-traded biopharmaceutical company.

Douglas Cole

Dr. Douglas G. Cole, M.D is an Independent Director of Agios Pharmaceuticals, Inc. Dr. Cole has been a general partner of Flagship Ventures, where he has focused on life science investments, since 2001. He currently serves on the board of directors of Receptos, Inc., a publically traded biopharmaceutical company and on the boards of directors of several private biopharmaceutical companies, including Ensemble Therapeutics, Quanterix Corporation, Permeon Biologics, Inc., and Syros Pharmaceuticals Inc. In the past five years Dr. Cole has served on the boards of Seventh Sense Biosystems, Inc., Resolvyx Pharmaceuticals, Inc., AVEO Pharmaceuticals, Inc., Tetraphase Pharmaceuticals, Inc., Concert Pharmaceuticals, Inc., Selecta Biosciences, Inc., Avedro, Inc., Zalicus, Inc. (formerly CombinatoRx), CGI Pharmaceuticals, and Morphotek Inc.

Kaye Foster-Cheek

Ms. Kaye I. Foster-Cheek is an Independent Director of the Company. Ms. Foster-Cheek has more than 25 years of experience in human resources in the pharmaceutical industry. At Onyx, which was acquired by Amgen in 2013, Ms. Foster-Cheek was senior vice president of global human resources and an executive team member. She led all aspects of human resources for U.S. and global operations. Prior to joining Onyx, Ms. Foster-Cheek was global vice president of human resources and an executive committee member at Johnson and Johnson from 2003 to 2010. Before Johnson and Johnson, Ms. Foster-Cheek held several senior human resources executive positions with Pfizer Inc. supporting its pharmaceuticals businesses in Japan, Asia, Africa, Middle East and Latin America and, notably, led the integration of both the Warner-Lambert and Pharmacia mergers for these regions. Prior to that, she gained 10 years of operational experience at The Yellow Pages. Ms. Foster-Cheek is also very active in her community and has received several awards for her work. She earned her undergraduate degree at Baruch College of the City University of New York and received her MBA from Columbia University, Graduate School of Business.

Perry Karsen

Mr. Perry A. Karsen is an Independent Director of Agios Pharmaceuticals, Inc. Mr. Karsen currently serves as the chief executive officer of the Celgene Cellular Therapeutics division of Celgene Corporation, a publicly-traded global biopharmaceutical company, and as executive vice president of Celgene Corporation. Mr. Karsen served as chief operations officer of Celgene from July 2010 to May 2013, and as senior vice president and head of worldwide business development of Celgene from 2004 to 2009. Between February 2009 and July 2010, Mr. Karsen was chief executive officer of Pearl Therapeutics, a privately held biotechnology company. Prior to his tenure with Celgene, Mr. Karsen held executive positions at Human Genome Sciences, Bristol-Myers Squibb, Genentech and Abbott Laboratories. In addition, Mr. Karsen served as a general partner at Pequot Ventures. Mr. Karsen serves as a member of the boards of directors of the Biotechnology Industry Organization (BIO), BayBio and the Life Sciences Foundation. Mr. Karsen has a Masters of Management degree from Northwestern University’s Kellogg Graduate School of Management, a Masters in Teaching of Biology from Duke University, and a B.S. in Biological Sciences from the University of Illinois, Urbana-Champaign.

John Maraganore

Dr. John M. Maraganore, Ph.D. is an Independent Director of Agios Pharmaceuticals, Inc. Dr. Maraganore has served as the chief executive officer and as a director of Alnylam Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company. From December 2002 to December 2007, Dr. Maraganore served as president of Alnylam. From April 2000 to December 2002, Dr. Maraganore served as senior vice president, strategic product development with Millennium. Before Millennium, he served as director of molecular biology and director of market and business development at Biogen, Inc. (now Biogen Idec, Inc.), a publicly-traded company. Prior to Biogen, Dr. Maraganore was a scientist at ZymoGenetics, Inc. and The Upjohn Company. Dr. Maraganore is also chairman of the board of directors of Regulus Therapeutics, Inc., a publicly-traded company, and a director of bluebird bio, Inc. and Tempero Pharmaceuticals. In addition, he is a venture partner at Third Rock Ventures, L.P., where he participates in a limited capacity focusing on guiding strategy for Third Rock and its portfolio companies. He is also a member of the Immunology Advisory Council of Harvard Medical School and a member of the board of directors of the Biotechnology Industry Organization.

Robert Nelsen

Mr. Robert T. Nelsen is an Independent Director of Agios Pharmaceuticals, Inc. Mr. Nelsen was a co-founder of ARCH Venture Partners, a venture capital firm, and has served in various capacities for ARCH and affiliated entities since July 1986. Mr. Nelson is currently a managing director of ARCH Venture Corporation. Mr. Nelsen has played a significant role in the early sourcing, financing and development of more than 30 companies. Mr. Nelsen is a director of Ikaria, Inc., Kythera Biopharmaceuticals, Inc., Sapphire Energy, Inc., Fate Therapeutics, Inc., Ensemble Therapeutics Corporation, NeurogesX, Inc., Bellerophon Therapeutics, LLC, Juno Therapeutics, Inc., SAGE Therapeutics Inc., Syros Pharmaceuticals Inc., and serves as chairman of the board of Hua Medicine. Mr. Nelsen also serves as a Trustee of the Fred Hutchinson Cancer Research Institute, the Institute for Systems Biology, and is a director of the National Venture Capital Association. Mr. Nelsen previously served on the boards of Illumina, Inc, Ikaria Inc., Caliper Life Sciences, Inc, Adolor Corporation, Receptos, Inc., and entities affiliated with deCode Genetics, Inc, among others. Mr. Nelsen received a B.S. with majors in Biology and Economics from the University of Puget Sound and an M.B.A. from the University of Chicago.

Kevin Starr

Mr. Kevin P. Starr is an Independent Director of Agios Pharmaceuticals, Inc. Mr. Starr has been a Partner of Third Rock Ventures, a venture capital firm. From January 2003 to March 2007, Mr. Starr was an entrepreneur. From December 2001 to December 2002, Mr. Starr served as chief operating officer of Millennium. He also served as Millennium’s chief financial officer from December 1998 to December 2002. Mr. Starr currently serves on the board of directors of Alnylam. Mr. Starr also serves on the boards of Zafgen, Inc., PanOptica, Inc., MyoKardia, Inc., Global Blood Therapeutics, Inc., Afferent Pharmaceuticals, and SAGE Therapeutics.

Marc Tessier-Lavigne

Dr. Marc Tessier-Lavigne, Ph.D. is an Independent Director of Agios Pharmaceuticals, Inc. Dr. Tessier-Lavigne has served as president of the Rockefeller University, as well as professor and Head of the Laboratory of Brain Development and Repair, since 2011. Previously, he was employed at Genentech, Inc. from 2003 to 2011, where he became executive vice president for research and chief scientific officer, and directed 1,400 people in disease research and drug discovery in cancer, immune disorders, infectious diseases and neurodegenerative diseases. Prior to his tenure at Genentech, Dr. Tessier-Lavigne was an investigator with the Howard Hughes Medical Institute from 1994 to 2003 and a professor at Stanford University and the University of California, San Francisco from 1991 to 2003. He is a member of the Board of Directors of Pfizer Inc. and Regeneron Pharmaceuticals Inc. He is a member of the National Academy of Sciences and its Institute of Medicine, and a fellow of the Royal Society (UK), the Royal Society of Canada, the American Academy of Arts and Sciences, the American Association for the Advancement of Science, and the Academy of Medical Sciences (UK). Dr. Tessier-Lavigne earned undergraduate degrees from McGill University and from Oxford University, where he was a Rhodes Scholar. He received his Ph.D. from University College London, and conducted postdoctoral work at the MRC Developmental Neurobiology Unit in London and at Columbia University.

Glenn Goddard

Mr. Glenn Goddard is Senior Vice President - Finance for Agios Pharmaceuticals, Inc., effective August 28, 2013. He worked at Archemix, a privately held biopharmaceutical company, where he served as the Vice President of Finance. He was the Corporate Controller of ImmunoGen, Inc., a publicly traded oncology-focused biopharmaceutical company. Earlier in his career, he was an Audit Supervisor within the Technology, Communication and Entertainment group of Ernst & Young and an Audit Manager at Feeley & Driscoll.
Search Stocks